Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-γ production by altering cellular metabolism via arginase-1

Journal of Immunology

Volumn 196, Issue 5, 2016, Pages 2283-2292

  Goh, Celeste C ^a   Roggerson, Krystal M ^a   Lee, Hai Chon ^a,b   Golden Mason, Lucy ^c   Rosen, Hugo R ^c   Hahn, Young S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; CD33 ANTIGEN; GAMMA INTERFERON; GRANZYME B; MAMMALIAN TARGET OF RAPAMYCIN; ARGINASE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CD33+ PERIPHERAL BLOOD MONONUCLEAR CELL; CELL INTERACTION; CELL METABOLISM; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MYELOD DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; CELL LINE; GENETICS; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; RNA PROCESSING; SIGNAL TRANSDUCTION; VIROLOGY;

ARGINASE; ARGININE; CELL LINE; CELLS, CULTURED; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MYELOID CELLS; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIALIC ACID BINDING IG-LIKE LECTIN 3; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84962018955     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501881     Document Type: Article

References (60)

1. Chinnadurai, R., V. Velazquez, and A. Grakoui. 2012. Hepatic transplant and HCV: a new playground for an old virus. Am. J. Transplant. 12: 298-305.
2. Roohvand, F., and N. Kossari. 2011. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin. Ther. Pat. 21: 1811-1830.
3. Hoofnagle, J. H. 1997. Hepatitis C: the clinical spectrum of disease. Hepatology 26(3 Suppl. 1): 15S-20S.
4. Tacke, R. S., A. Tosello-Trampont, V. Nguyen, D. W. Mullins, and Y. S. Hahn. 2011. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J. Biol. Chem. 286: 10847-10855.
5. Hahn, Y. S. 2003. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr. Opin. Immunol. 15: 443-449.
6. Lee, H.-C., S.-S. J. Sung, P. D. Krueger, Y.-A. Jo, H. R. Rosen, S. F. Ziegler, and Y. S. Hahn. 2013. Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology 57: 1314-1324.
7. Urbani, S., B. Amadei, P. Fisicaro, D. Tola, A. Orlandini, L. Sacchelli, C. Mori, G. Missale, and C. Ferrari. 2006. Outcome of acute hepatitis C is related to virusspecific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44: 126-139.
8. Hartling, H. J., J. C. Gaardbo, A. Ronit, L. S. Knudsen, H. Ullum, B. Vainer, M. R. Clausen, K. Skogstrand, J. Gerstoft, and S. D. Nielsen. 2012. CD4+ and CD8+ regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Scand. J. Immunol. 76: 294-305.
9. Amadei, B., S. Urbani, A. Cazaly, P. Fisicaro, A. Zerbini, P. Ahmed, G. Missale, C. Ferrari, and S. I. Khakoo. 2010. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138: 1536-1545.
10. Doherty, D. G., and C. O'Farrelly. 2000. Innate and adaptive lymphoid cells in the human liver. Immunol. Rev. 174: 5-20.
11. Sun, H., C. Sun, Z. Tian, and W. Xiao. 2013. NK cells in immunotolerant organs. Cell. Mol. Immunol. 10: 202-212.
12. Mandelboim, O., P. Malik, D. M. Davis, C. H. Jo, J. E. Boyson, and J. L. Strominger. 1999. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. USA 96: 5640-5644.
13. Walzer, T., M. Dalod, E. Vivier, and L. Zitvogel. 2005. Natural killer celldendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. 5(Suppl. 1): S49-S59.
14. Tu, Z., A. Bozorgzadeh, R. H. Pierce, J. Kurtis, I. N. Crispe, and M. S. Orloff. 2008. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205: 233-244.
15. Ahlenstiel, G., B. Edlich, L. J. Hogdal, Y. Rotman, M. Noureddin, J. J. Feld, L. E. Holz, R. H. Titerence, T. J. Liang, and B. Rehermann. 2011. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141: 1231-1239, 1239.e1-2.
16. Zeromski, J., I. Mozer-Lisewska, M. Kaczmarek, A. Kowala-Piaskowska, and J. Sikora. 2011. NK cells prevalence, subsets and function in viral hepatitis C. Arch. Immunol. Ther. Exp. (Warsz.) 59: 449-455.
17. Poli, A., T. Michel, M. Thérésine, E. Andrès, F. Hentges, and J. Zimmer. 2009. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126: 458-465.
18. Fan, Y.-Y., B.-Y. Yang, and C.-Y. Wu. 2008. Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs. Cell Biol. Int. 32: 188-197.
19. Gonzalez, V. D., K. Falconer, N. K. Björkström, K. G. Blom, O. Weiland, H.-G. Ljunggren, A. Alaeus, and J. K. Sandberg. 2009. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J. Immunol. 183: 6612-6618.
20. Goh, C., S. Narayanan, and Y. S. Hahn. 2013. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol. Rev. 255: 210-221.
21. Tacke, R., H.-C. Lee, C. Goh, J. Courtney, S. J. Polyak, H. R. Rosen, and Y. S. Hahn. 2012. Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology 55: 343-353.
22. Ganeshan, K., and A. Chawla. 2014. Metabolic regulation of immune responses. Annu. Rev. Immunol. 32: 609-634.
23. Pearce, E. L., and E. J. Pearce. 2013. Metabolic pathways in immune cell activation and quiescence. Immunity 38: 633-643.
24. Pearce, E. L., M. C. Poffenberger, C.-H. Chang, and R. G. Jones. 2013. Fueling immunity: insights into metabolism and lymphocyte function. Science 342: 1242454.
25. Albert, V., and M. N. Hall. 2015. mTOR signaling in cellular and organismal energetics. Curr. Opin. Cell Biol. 33: 55-66.
26. Marçais, A., J. Cherfils-Vicini, C. Viant, S. Degouve, S. Viel, A. Fenis, J. Rabilloud, K. Mayol, A. Tavares, J. Bienvenu, et al. 2014. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15: 749-757.
27. Nandagopal, N., A. K. Ali, A. K. Komal, and S.-H. Lee. 2014. The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions. Front. Immunol. 5: 187.
28. Altomare, D. A., and A. R. Khaled. 2012. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr. Med. Chem. 19: 3748-3762.
29. Gingras, A. C., S. G. Kennedy, M. A. O'Leary, N. Sonenberg, and N. Hay. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12: 502-513.
30. Sonenberg, N., and A. C. Gingras. 1998. The mRNA 59 cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10: 268-275.
31. Avruch, J., X. Long, S. Ortiz-Vega, J. Rapley, A. Papageorgiou, and N. Dai. 2009. Amino acid regulation of TOR complex 1. Am. J. Physiol. Endocrinol. Metab. 296: E592-E602.
32. Gulati, P., L. D. Gaspers, S. G. Dann, M. Joaquin, T. Nobukuni, F. Natt, S. C. Kozma, A. P. Thomas, and G. Thomas. 2008. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab. 7: 456-465.
33. Chen, R., Y. Zou, D. Mao, D. Sun, G. Gao, J. Shi, X. Liu, C. Zhu, M. Yang, W. Ye, et al. 2014. The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation. J. Cell Biol. 206: 173-182.
34. Showkat, M., M. A. Beigh, and K. I. Andrabi. 2014. mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions. Mol. Biol. Int. 2014: 686984.
35. Boultwood, J., B. H. Yip, C. Vuppusetty, A. Pellagatti, and J. S. Wainscoat. 2013. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5qsyndrome and other ribosomopathies. Adv. Biol. Regul. 53: 8-17.
36. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102: 9294-9299.
37. Golden-Mason, L., and H. R. Rosen. 2013. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol. Rev. 255: 68-81.
38. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
39. Hildeman, D. A., T. Mitchell, T. K. Teague, P. Henson, B. J. Day, J. Kappler, and P. C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10: 735-744.
40. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13: 828-835.
41. Nagaraj, S., A. G. Schrum, H.-I. Cho, E. Celis, and D. I. Gabrilovich. 2010. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184: 3106-3116.
42. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 5839-5849.
43. Morris, S. M., Jr. 2009. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157: 922-930.
44. Kong, X., B. Tan, Y. Yin, H. Gao, X. Li, L. A. Jaeger, F. W. Bazer, and G. Wu. 2012. L-Arginine stimulates the mTOR signaling pathway and protein synthesis in porcine trophectoderm cells. J. Nutr. Biochem. 23: 1178-1183.
45. Laplante, M., and D. M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293.
46. Cao, W., B. Sun, M. A. Feitelson, T. Wu, R. Tur-Kaspa, and Q. Fan. 2009. Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int. J. Cancer 124: 2886-2892.
47. Cai, W., A. Qin, P. Guo, D. Yan, F. Hu, Q. Yang, M. Xu, Y. Fu, J. Zhou, and X. Tang. 2013. Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. J. Clin. Immunol. 33: 798-808.
48. Pallett, L. J., U. S. Gill, A. Quaglia, L. V. Sinclair, M. Jover-Cobos, A. Schurich, K. P. Singh, N. Thomas, A. Das, A. Chen, et al. 2015. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat. Med. 21: 591-600.
49. Zeng, Q.-L., B. Yang, H.-Q. Sun, G.-H. Feng, L. Jin, Z.-S. Zou, Z. Zhang, J.-Y. Zhang, and F.-S. Wang. 2014. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR z chain expression on CD8(+) T cells in chronic hepatitis C patients. Mol. Cells 37: 66-73.
50. Lamas, B., J. Vergnaud-Gauduchon, N. Goncalves-Mendes, O. Perche, A. Rossary, M.-P. Vasson, and M.-C. Farges. 2012. Altered functions of natural killer cells in response to L-Arginine availability. Cell. Immunol. 280: 182-190.
51. Oberlies, J., C. Watzl, T. Giese, C. Luckner, P. Kropf, I. Müller, A. D. Ho, and M. Munder. 2009. Regulation of NK cell function by human granulocyte arginase. J. Immunol. 182: 5259-5267.
52. Felmlee, D. J., D. A. Sheridan, S. H. Bridge, S. U. Nielsen, R. W. Milne, C. J. Packard, M. J. Caslake, J. McLauchlan, G. L. Toms, R. D. G. Neely, and M. F. Bassendine. 2010. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 139: 1774-1783, 1783.e1-6.
53. Bratke, K., M. Kuepper, B. Bade, J. C. Virchow, Jr., and W. Luttmann. 2005. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol. 35: 2608-2616.
54. Hodge, D. L., A. Martinez, J. G. Julias, L. S. Taylor, and H. A. Young. 2002. Regulation of nuclear gamma interferon gene expression by interleukin 12 (IL- 12) and IL-2 represents a novel form of posttranscriptional control. Mol. Cell. Biol. 22: 1742-1753.
55. De Maria, A., F. Bozzano, C. Cantoni, and L. Moretta. 2011. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc. Natl. Acad. Sci. USA 108: 728-732.
56. Moretta, L. 2010. Dissecting CD56dim human NK cells. Blood 116: 3689-3691.
57. Sojka, D. K., B. Plougastel-Douglas, L. Yang, M. A. Pak-Wittel, M. N. Artyomov, Y. Ivanova, C. Zhong, J. M. Chase, P. B. Rothman, J. Yu, et al. 2014. Tissueresident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife 3: e01659.
58. Radaeva, S., R. Sun, B. Jaruga, V. T. Nguyen, Z. Tian, and B. Gao. 2006. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2Ddependent and tumor necrosis factor-related apoptosis-inducing liganddependent manners. Gastroenterology 130: 435-452.
59. Cheng, C.-W., C. C. Duwaerts, Nv. Rooijen, P. Wintermeyer, S. Mott, and S. H. Gregory. 2011. NK cells suppress experimental cholestatic liver injury by an interleukin-6-mediated, Kupffer cell-dependent mechanism. J. Hepatol. 54: 746-752.
60. Wang, J., R. Sun, H. Wei, Z. Dong, B. Gao, and Z. Tian. 2006. Poly I:C prevents T cell-mediated hepatitis via an NK-dependent mechanism. J. Hepatol. 44: 446-454.